



10th November 2009

Companies Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

**ASX ANNOUNCEMENT / MEDIA RELEASE
ENTITLEMENT ISSUE UPDATE AND 15% PLACEMENT**

The Board of Anteo Diagnostics Limited ("ADO") is pleased to announce that today it has issued and allotted and dispatched holding statements relating to:

1. **140,878,914 Fully Paid Ordinary Shares;** and
2. **140,878,914 Options:** Each Option having an exercise price of \$0.012 and an expiry date of 30th September 2010.

these being the Shortfall Securities applied for pursuant to the Company's Prospectus dated 18th September 2009 and which now finalises the issue of all Shares and Options relating to the Company's Entitlement Issue.

As a result of the underlying demand from the Entitlement Issue and to add to the working capital of the Company, the Board has also resolved to undertake an additional Placement to sophisticated investors through the issue of:

1. **58,333,333 Fully Paid Ordinary Shares** ("Placement Shares") at an issue price of \$0.006 per share; and
2. **58,333,333 Options:** Each Option having an exercise price of \$0.012 and an expiry date of 30th September 2010 ("Placement Options") and a nil issue price

to raise a total of \$350,000.00.

The Company notes that currently it only has sufficient capacity pursuant to ASX Listing Rule 7.1 to issue 39,500,000 of the Placement Shares and therefore will need to call an extraordinary meeting of shareholders to seek approval for the issue of the balance of the Placement Shares being 18,833,333 and all of the Placement Options.

For further information please contact:

Dr Geoff Cumming, CEO, Anteo Diagnostics Limited
Tel: +612 8823 3110

Mr James Henderson, Non Executive Chairman, Anteo Diagnostics Limited
Tel: +612 8823 3100

***Anteo Diagnostics Limited* ABN 78 090 487 273**
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

For personal use only



anteo diagnostics
l i m i t e d

About Anteo

Anteo Diagnostics is an Australian company specializing in the design and assembly of multi-component coatings for the solid phase of immunoassay and the use of those coatings in biomarker development. Anteo's proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. This results in dramatically improved immunoassay performance such as better sensitivity, and cost savings such as batch-to-batch reproducibility. Anteo applies its coatings to develop novel biomarkers for a range of diseases. Anteo works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.anteodx.com.

For personal use only

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com